Gedeon Richter Archives -

Around 4,500 women in the UK will be eligible for treatment with Gedeon Richter’s once-daily oral therapy Ryeqo,

Gedeon Richter gets NICE nod for uterine fibroids drug Ryeqo

https://pharmaphorum.com/news/gedeon-richter-gets-nice-nod-for-uterine-fibroids-drug-ryeqo/

Two biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

https://pharmaphorum.com/news/lilly-faces-biosimilar-rivals-to-osteoporosis-drug-forsteo-in-europe/

Companies want Vraylar as option bipolar depression

Allergan and Gedeon Richter set to expand use of bipolar drug

https://pharmaphorum.com/news/allergangedeon-richter-aim-expand-use-bipolar-drug/

Patient groups slam pharma over drug costs in latest survey.

Drug price controversies hit pharma’s reputation

https://pharmaphorum.com/news/drug-price-pharma-reputation/

Allergan and Gedeon Richter’s uterine fibroid treatment ulipristal acetate, has succeeded in a phase 3 trial ahead of

Allergan/Gedeon Richter’s uterine fibroids drug succeeds in Phase 3

https://pharmaphorum.com/news/allergan-gedeon-richters-uterine-fibroids-drug-succeeds-in-phase-3/

Gedeon Richter